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an Orator and the 16th Malcolm Jones Lecer, MIR Director Ronald Evens spoke on "The Hisy of Postgraduate Education in Radiology" at the
April meeting of the American Association of Academic Chief Residents in Radiology (A3CR2). In recognition of 100 years of achievements in the radiation
sciences, throughout the year radiology leaders will
present Hartman Orations at society and educational
meetings worldwide. The orations are named in
honor of the late Dr. Glen Hartman, a professor of
--

radiology at the Mayo Clinic, who spearheaded the
Radiology Centennial.
After the lecture Evens gathered with MIR diagnostic
radiology residents (left to right) Farrel Van
Wagenen, 1995-1996 cochief; Cynthia Rigsby, '94'95 chief; Eric Weidman, '95-'96 chief; and Sean
Muldowney, '94-'95 cochief.

REFLECTIONS

Wielm Conrad Roentgen would be amazed at
he advances made in radiology since 1 895
wherThe
whenhe produced that first picture of the bones in his
wife's hand. And Doctors Warren Cole, Glover Copher,
Evarts Graham, and Sherwood Moore of Washington
University would be proud that their first gallbladder
visualization was the impetus for building what has
become one of the world's premier radiological institutions — MALLINCKRODT INSTITUTE.
In the 64 years since the Institute began operation, MIR scientists and clinicians have provided
essential information for the diagnosis and
treatment of diseases. From the development of
roentgen kymography and positron emission
tomography to the first medical application of
isotopes, from identifying clinical applications
for three-dimensional imaging to functional
mapping of the brain — all of this groundbreaking research, and more, has come out of
MaUinckrodt Institute of Radiology.
At MIR, scientists and clinicians are committed to providing the highest quality health care possible. Through their search to DISCOVER newer and
better methods for TREATING and HEALING diseases, the quality of life for thousands of patients has
already improved.

The following pages provide

updates on some of that research and the changes
affecting the Institute.

MALLINCKRODT INSTITUTE OF RADIOLOGY
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PATIENT CARE
REFLECTIONS
The affiliation be
tween Washington
University School of Medicine

(WUMS)

and

Barnes Hospital began
over 80 years ago. Back
in October of 1911, a contract was drawn up with
the provisions that the
yet-to-be-built hospital
would not only be staffed
by WUMS faculty but
would serve as the home
base for the School's
research and medical
education.

ince it first opened in 1931, the Institute has provided diagnostic radiology services
for Barnes and, later, for Children's Hospital of St. Louis. Within the last five years,
MIR's responsibility for diagnostic services dramatically increased. Robert Levitt, MD,
director of radiology at Barnes West County Hospital, coordinated the EXPANSION of diagnostic services at this satellite hospital and, in the past academic year,
produced a volume increase of more than 25 percent over previous years. Since early
1994, Scott Mirowitz, MD, radiologist-in-chief, has guided a renovation of the diagnostic radiology facilities at Jewish Hospital. In July of 1994, William Dawson, MD, was
appointed radiologist-in-chief of Mallinckrodt Institute's Department of Radiology at
Barnes St. Peters Hospital. Plans are underway to include additional services and to
enlarge the diagnostic clinical areas.
In 1948, MIR's Radiation Oncology Center first offered high-energy radiation
therapy to Barnes Hospital patients who were diagnosed with cancer, and the program
was expanded in late 1983 to include Jewish Hospital. Subsequent years were marked
by refinements in treatment techniques and a steady increase in treatment programs,
with a tremendous growth spurt in 1994: a three-dimensional planning and quality
assurance facility; a brachytherapy lab where physicists develop better methods for
targeting cancers with sealed, radioactive isotopes; and, a simultaneous hyperthermia
and external beam program at Jewish Hospital for treating small and large superficial
tumors.
The Institute's soon-to-be 30-year-old Division of Nuclear Medicine provides
diagnostic nuclear medicine procedures at Barnes, Jewish, and Children's hospitals
and consultation services at Barnes West County and Barnes St. Peters. During the
1993-1994 academic year, MIR introduced the St. Louis region's FIRST NUCLEAR
IMAGING with the gamma-emitting compound OctreoscanR. Collaborating with
clinicians in the WUMS Cardiovascular Division, nuclear medicine physicians have laid
the groundwork for an integrated cardiac stress imaging service.
By the end of 1994, the Institute was providing professional services for five
hospitals, and another superlative — the largest academic radiology department in
the United States — was added to MIR's list of recognitions. While bigger is not synonymous with better, the Institute proved that additional clinical responsibilities has
not altered our ultimate goal: providing patients and their physicians with the highest
quality radiology services. In a recent Barnes Hospital Physician Satisfaction Survey,
referring physicians rated their level of satisfaction with medical services, and MIR's
diagnostic radiology and radiation oncology clinical areas each RECEIVED TOP
RATINGS, an impressive 94 percent "very satisfied." lilllil
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RESEARCH
REFLECTIONS
Life is a gamble, butk
perhaps no one
more aware of that gam
ble than the seven million patients in the
United States who have
CORONARY
ARTERY DISEASE.
With this disease, fatty
deposits line the arteries
supplying blood to the
heart muscle.

When

those deposits harden

l

and obstruct blood flow
in the arteries, odds are
high that the patient will
experience pronounced
chest pain or a heart
attack.

The odds are

even greater that part of
the heart muscle will die.
Until now there was no
diagnostic procedure
that could accurately predict if the myocardium
was damaged but still
alive, or if patients
would

benefit from

angioplasty or surgery.

At Mallinckrodt Institute, DR. ROBERT GROPLER of the Division of Nuclear
Medicine has successfully used positron emission tomography (PET) to measure the
cofW«ions among blood flow, glucose utilization, and oxygen consumption in the
heart. Blood flow may be decreased but if oxygen and glucose are being used, then
the heart muscle is metabolically active. And viable muscle means the patient is a
good candidate for balloon angioplasty or bypass surgery.
In a three-year study of more than 100 patients, an oxygen usage measurement
with the radiolabeled compound 11C-acetate proved to be the most accurate PET measurement available to determine cardiac tissue viability. Study results are impressive.
Eighty-five percent of the patients diagnosed with viable heart muscle have improved
muscle function as a result of angioplasty or surgery, and they were either taken off
medication or the dosage was reduced. If the myocardium was determined to be nonviable, the PET diagnosis correctly predicted (90 percent) that metabolic function
would not return.
Now a routinely offered clinical test at the Institute, the 45-minute, CARDIAC
PET-with-acetate procedure is more time efficient than other diagnostic exams. Standard imaging with 18F-fluorodeoxyglucose (measures how much sugar the heart
metabolizes) takes nearly three hours to complete; thallium stress imaging, up to four
hours.
While continuing to track patient outcomes from the acetate study, Gropler will
use PET to explore another facet of cardiac metabolism — measuring the energy efficiency of heart muscle. As principal investigator of a five-year, National Institutes of
Health grant, Gropler, in collaboration with Washington University cardiologists, will
study a group of 200 patients, 45 to 70 years of age, who have had a heart attack.
"A normal heart operates at a high level of inefficiency, using only about thirty
percent of the energy produced from contraction," says Gropler. "A damaged heart
uses five percent or less. At Mallinckrodt Institute, we will conduct the first clinical
investigation into the entire spectrum of why blood flow abnormalities result in certain
myocardial functions and how we can improve energy usage."
The research has important implications for heart patients who often need
aggressive medical therapies. Currently, there is no measurement available to determine if these therapies are working. According to Gropler, the ability to measure efficiency will provide a way to measure how effective therapies are in improving cardiac
function.
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RESEARCH
REFLECTIONS
It has been 30 year,
since augmentation
mammoplasty was first
available in the United
States. And it has been
four years since the Food
and Drug Administration (FDA) banned the
silicone gel prosthesis
used for breast enlargement. The ban came on
the heels of thousands of
lawsuits claiming that
some women's illnesses
were caused by the leakage of silicone gel from
their implants.

But long before the national controversy over IMPLANTS hit the news, radiologists
at Mallinckrodt Institute were concerned about another problem stemming from augmentation mammoplasty: 22 to 83 percent of breast tissue was blocked on mammograms because of the implant's opacity to X rays, and that opacity could cause
early-stage breast cancer to go undetected. DRS. LOUIS GILULA, BARBARA MONSEES, and former colleague Judy Destouet were joined in their
search for a new, radiolucent breast implant filler by Leroy Young, a Washington University plastic surgeon, and JOHN EICHLING, PhD, an MIR medical physicist.
The first breakthrough came with Eichling's demonstration that triglyceride, a
naturally occurring fat that can be metabolized by the body, was similar in opacity to
normal breast tissue. After subsequent testing of experimental implants filled with
triglycerides (such as peanut and sunflower oils) provided positive results, the
researchers were awarded a patent for a radiolucent breast implant filler.
In August of 1994, the FDA approved a five-site, national study to pre-market
test TRILUCENTR, an implant filled with a natural fat from soybean oil. Trilucent,
manufactured by LipoMatrix Inc. of Palo Alto, California, in conjunction with the
Washington University-held patent, also contains a small computer chip (called a
transponder) that is individually coded and stores medical information about the
patient and the implant. The information, which can be noninvasively retrieved with
an electronic scanning device, will be entered into an international registry database
for future follow-up.
Women participating in the study all have augmentation implants that must be
removed because of leakage or other complications not related to systemic medical
problems. There are 10 patients at each of the five clinical trials — WASHINGTON
UNIVERSITY; Johns Hopkins University; The Breast Center in Van Nuys, California; the University of Florida in Gainesville; and Stanford University.
Study participants will receive medical follow-up for at least one year following
implantation. In addition to assessing the implant's radiolucency, researchers will
assess capsular scarring tendencies, anatomic benefit, and changes in the patient's
quality of life. Drs. Monsees and Young are principal investigators of the Washington
University study, where the first of the 50 patients received the Trilucent implant in
December. IUU
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approximately 500 critically ill patients worldwide who owed their
lives to a piece of metal
and an internentional
radiology

procedure

called TIPS — transjugular intrahepatic
portosystemic shunting.

REFLECTIONS

All of
ol the patients had developed life-threatening, esophageal or gastric bleeding prob,ems caused by chronic, progressive liver disease. When the blood flow between the
portal vein (transports blood from the bowel and spleen to the liver) and an hepatic
vein (receives blood from the liver) is blocked, pressure builds up in the portal vein
and causes bleeding. If the bleeding is not controlled, the patient can die.
There are methods other than TIPS that can treat the bleeding: endoscopic sclerotherapy or surgical portosystemic shunts. But both carry risks. Injecting solutions
into the esophagus to cause clotting carries a high incidence of recurrent bleeding and
up to a 20 percent complication rate. And although a surgical shunt will stop the hemorrhaging, the major surgery involved often results in high mortality rates, plus additional surgery is required to remove the shunt during liver transplantation.
At the Institute, DR. MICHAEL DARCY has led an interventional radiology team through 125 TIPS procedures to date. In TIPS, an expandable, metallic stent
is guided through a sheath placed in the patient's jugular vein and into the liver. This
shunt forms a NEW PATH FOR THE BLOOD FLOW and removes the
pressure from the portal vein. The MIR team has perfected the method of finding the
portal vein by modifying the angiographic techniques and using an innovative needle
system.
Hailed as a godsend by both patients and physicians, TIPS involves no surgery.
The procedure does require a local anesthetic and IV sedatives but is more easily tolerated by a critically ill patient than either of the alternatives. Downtime for the patient
is usually one or two days in the hospital. There are no complications if the patient
subsequently undergoes liver transplantation because the shunt is completely within
the liver and is removed with the liver during the transplant.
TIPS procedures were first done in the 1960s, using balloon dilation to open a
tract in the liver between the portal and hepatic veins. Results were not often good
because the pathway would quickly close down. The solution came in 1989 in the
form of a metal, balloon-expandable stent to permanently create a blood flow path.
As MIR's principal investigator in a Federal Drug Administration-approved, multicenter trial, Darcy is evaluating the efficacy of TIPS with a new self-expanding, flexible
stent. The three-year-old trial is nearing completion, and researchers are reporting good
results. The majority of the patients in the study have greatly benefitted from TIPS. EM
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RESEARCH
REFLECTIONS
From the shopping J
mall to the operat^J'ing room is an unlikely
progression

by

any

stretch of the imagination.

But technology

developed in 1983 to produce portrait sculptures
sold in U.S. shopping
malls is now used successfully by plastic surgeons in the pre- and
postoperative evaluation
of their patients.

About five years ago, MICHAEL VANNIER, MD, director of the Institute's
image processing lab, was contacted by researchers from a small St. Louis company
called Cencit, Inc. to help create a new market for their scanner. Vannier, a pioneer in
3-D IMAGING with expertise in congenital facial deformities, and a team of MIR
engineers designed software and techniques to convert an existing sensing device into
a medical facial-surface scanner.
The resulting three-dimensional surface digitizer produces a 360-degree examination of the head in less than one second. The free-standing, geodesic-shaped structure houses six cameras and six strobe-light projectors, which work on a "patterned
light" concept using ordinary white light. A zigzag pattern or grid, projected onto the
patient's face, produces 144 images. The images are processed into 3-D data for comparison with changes measured one day after surgery and again after two weeks.
In 1991, Vannier and Leroy Young, MD, Washington University plastic and
reconstructive surgeon, conducted a study of the new imaging system. The first
patient was a 41-year-old female who underwent facial plastic surgery: forehead lift,
eyelid surgery, chin implant, and facelift. Study results prove the system's ACCURACY IN MEASURING CHANGES resulting from surgery and in identifying
and quantifying postoperative facial edema. The system's ability to distinguish
changes due to surgery from those due to edema aids surgeons in prescribing steroidal
therapy for patients. By modifying the data, surgeons can show their patients a computerized preview of the postoperative results and can calculate the correct size,
shape, and volume of an implant.
Encouraged by the success of the facial scanner, Vannier and the research team
are exploring suitable APPLICATIONS FOR WHOLE-BODY SCANNING,
such as orthotic and prosthetic design, breast reconstruction surgery, reduction and
augmentation mammoplasty, scoliosis assessment, and radiation treatment planning.
Vannier, a consultant to the Advisory Group for Aerospace Research and Development
(NATO's oldest scientific and technical arm), says his motivation for whole-body scanning research comes from the group's quest for a multinational standard-sizing system.
Vannier hopes to use 3-D surface imaging techniques, coupled with the expertise of
Michael Miller, a Washington University electrical engineering professor recognized
for his mathematical evaluations of shape and size variations, to produce a universal
measurement system for medical, governmental, and industrial applications. Aillii
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REFLECTIONS
\piral

comput

'tomography (CT):
technology that promise
to be less invasive, less
costly, and as equally
effective as other procedures in diagnosing diseases.

Across

the

country, researchers are
conducting large-scale
studies to determine
whether spiral CT can
make good on those
promises.

Helical or spiral CT operates on a slip-ring technology; the X-ray tube and detector
>tate continuously in a 360-DEGREE SPIRAL MOTION around the patient.
Sincjpe patient takes only a single breath-hold (as compared to one, five-second
breath-hold for each of the 24 slices on conventional CT), the risk of respiratory misregistration and motion artifacts on the scan is virtually eliminated. Total scanning
time ranges from a few seconds up to one-half minute, as compared to two to three minutes with conventional CT, and the imaging quality of the two technologies is comparable.
But in an era where health care dollars are under scrutiny, the cost-effectiveness of spiral CT is being questioned. Proponents claim that SPIRAL CT can produce high quality scans while using less contrast media. Opponents of this theory are
concerned that to be competitive financially, the dose of contrast media would be
reduced to levels that affect the quality of the scan and, ultimately, the diagnosis.
At Mallinckrodt Institute, JAMES BRINK, MD, is principal investigator of
a chest and abdominal study to determine the optimal dosage and delivery method of
contrast media used with spiral CT. The Institute's 800-patient study is funded by
the Society of Computed Body Tomography and Magnetic Resonance and by
Nycomed Incorporated (formerly Sanofi Winthrop). The chest portion of the study is
nearly complete, with 75 of the 300 patients remaining to be scanned using low-dose
protocols. The completed, abdominal portion of the study involved 487 patients, randomly placed into 17 groups. Eight groups received contrast injected at a constant,
single rate (called uniphasic); 9 groups received a higher injection rate at the beginning of the scan, a slower rate near the end (biphasic).
The abdominal scans showed that uniphasic injection universally provided better results than did biphasic injection. For patients weighing less than the groups'
mean average of 183 pounds, the uniphasic dose could be reduced by up to 50 percent
and still produce acceptable levels of enhancement. (Based on the number of scans
performed by a radiology facility, this dose reduction could translate into an annual
cost savings of approximately $50,000.) In addition, dose reduction would be beneficial for patients with renal problems or for those patients who must undergo simultaneous scanning of the head, neck, chest, or pelvic areas. Iiliiil
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REFLECTIONS
An interactive soft'^1
ware package developed in Mallinckrodt
Institute's radiation
physics labs is adding
another dimension to the
radiotherapy treatment
of brain tumors. During
the past two years, as
principal investigator
for a contract from
Kanematsu Medical Systems

of

ROBERT
MALA,

Tokyo,
DRZY-

PhD, has

developed and fine-tuned
a portable software package for

visualizing

anatomy and radiation
doses in multiple twodimensional and threedimensional views. The
technology will be tested
within the year in clinical trials at Jewish
Hospital.

The software package can run on high-end workstations that support X-windows.
Used in tandem with imaging equipment such as computed tomography, positron
emission tomography, magnetic resonance, and digital angiography, the software is a
boon to radiotherapy treatment planning — both for the clinician and the patient.
While the current system for simulating and planning STEREOTACTIC
RADIOTHERAPY is effective, dose calculations are formatted two-dimensionally,
one angle at a time. Coupled with a slow workstation, the treatment planning routine
is long and laborious. The new software dovetails with the Institute's 3-D treatment
planning system, with a special modification for the brain. This modification provides
input for locating the center of radiation beams and for calculating radiation doses.
During the scanning procedure, the patient's head is immobilized with a stereotactic frame that appears as dots on the scans. This DOT PATTERN indicates a
definitive coordinate system that targets the radiation beam within one millimeter of
the tumor. The high-speed workstation immediately shows multiple 2-D and 3-D
views of the target area with 3-D dose distributions. Since both the planning and treatment usually can be accomplished in one day, the method is cost-effective, time efficient, and less stressful to the patient.
The system also can aid neurosurgeons in planning brain tissue biopsies;
implanting devices used in functional disorders, such as epilepsy, to chemically or
physiologically manipulate brain tissue; and in treating arterial venous malformations
and other vascular abnormalities.
Drzymala and coinvestigators JOSEPH SIMPSON, MD, PhD, a radiation oncologist, and Keith Rich, MD, a neurosurgeon, plan to further develop the software to include an expanded marking or coordinate system for analyzing anatomy
orientations. Then, the cumbersome stereotactic frame now used can be replaced
with a simpler version. A 3-D digitizer will locate the markers established during the
initial treatment planning and transfer the coordinates to the radiotherapy equipment,
allowing patients to be treated in an accurate, reproducible pattern, illlll
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Eiou say that John or
ary has a certain
glow about them, you are
usually referring to their
supposed good health.
When researchers in
MIR's Radiation Sciences laboratories talk
about a certain glow,
they are probably discussing studies using
positron

emission

tomography (PET) and
the glow emitted by a
tiny, metal-bearing peptide — studies that
promise to reclaim good
health
patients.

for

cancer

For m any years, researchers have known that cancers grow more rapidly if they carry
receptors for specific hormones naturally produced within the body. If scientists can
se radiolabeled, manmade hormones (called octreotide) that will attach to the cancer
cells, then the cell growth can be slowed or stopped. And if researchers can produce
on-site a less expensive alternative to the commercially produced octreotides, then
research dollars can be better applied to the fight against cancer.
Receptors for one of these natural hormones, SOMATOSTATIN, are carried by cancerous cells in the neuroendocrine system as well as tumors of the
prostate, breast, and lung. In the summer of 1994, as principal investigator, CAROLYN ANDERSON, PhD, received a five-year, National Institutes of Health
grant to evaluate whether or not radiolabeled octreotide would bind to cancer cells
containing somatostatin receptors.
Anderson and her research team have now developed two octreotide analogs
for radiolabeling with copper-64 and have evaluated the analogs in cells and in animal
models. By labeling octreotide with copper-64, a positron-emitting metal, the scientists plan to set a trap: If the cells carrying somatostatin receptors bind with
octreotide, the sites will glow when scanned with PET. Successful results would give
oncologists a powerful tool in the diagnosis or treatment of certain cancers.
Details of the team's octreotide syntheses were published in the Journal of
Medicinal Chemistry. The evaluation of the radiolabeled analogs is scheduled to
appear in the Journal of Nuclear Medicine.
The next phase of Anderson's research is a COLLABORATIVE CLINICAL STUDY of small cell lung cancer (SCLC) tumors. In previous clinical studies
using a gamma-emitting compound, large concentrations of somatostatin receptors
were found in SCLC tumors. Anderson will work with FARROKH
DEHDASHTI, MD, principal investigator of the clinical protocol, to evaluate
somatostatin-receptor levels in SCLC tumors imaged by positron emission tomography and a copper-64 labeled octreotide analog.
"Our goal is to define the potential role of PET utilizing copper-64 labeled
octreotide as a noninvasive imaging technique in the management of SCLC," says
Anderson. "If successful, we hope to expand the use of positron-emitting octreotide
analogs and PET to include the management of other somatostatin-receptor positive
tumors." EH
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RESEARCH
REFLECTIONS
A nine-year-old "newcomer" — threedimensional radiation
treatment planning and
conformal therapy — is
rapidly joining the
ranks of traditional
radiation
oncology
armamentarium.
Buoyed by the increasing numbers of radiation oncology centers
worldwide that are recognizing the value of 3-D
treatment,
MIR's

JAMES

PURDY,

PhD, one of the technology's pioneers, proposes
that "radiation oncology
will be an integrated,
image-based medicine
within five years."

Three-dimensional treatment planning began in 1986 as a call to action by the National
Cancer Institute: Create a program for delivering high-energy radiation safely and
more precisely to the tumor site while sparing surrounding healthy tissue. Including
MIR, six institutions nationwide were involved in developing the groundbreaking technology. Purdy, chief of radiation physics, was principal investigator for two research
contracts that led to the development of a 3-D dose planning system. The technology
was later approved by the Food and Drug Administration and is now sold commercially.
The St. Louis area's first 3-D TREATMENT PLANNING center opened
at Mallinckrodt Institute in July of 1992. The center, housed in the radiation physics
area on the sixth floor of Barnard Hospital, was equipped with an existing computed
tomography (CT) scanner fitted with a special laser marking system and connected to
a 3-D treatment planning computer.
At MIR, treatment for 50 percent of patients requiring advanced planning is prescribed through the 3-D program; the most prevalent application is for lung and
PROSTATE cancer. During the last year, workstations interfaced with 3-D planning
systems were installed in the radiation oncology clinical areas at Barnes and Jewish
hospitals and in the radiation physics preplanning room. At the heart of these systems
is a new, commercially produced CT SIMULATOR with an integrated laser marking system. The addition of multileaf collimation — devices installed on two linear
accelerators and connected over the computer network to the planning system —
provides conformal therapy for an average of 40 patients per month.
A Quality Assurance Center, established in late 1994, is the clearinghouse for
patient data submitted by nine facilities participating in a national dose escalation protocol for localized carcinoma of the prostate. After each case is reviewed by a threeman assessment team (Purdy; Dr. Jeff Michalski, a radiation oncologist; and William
Harms, a radiation physicist), results will be stored in a Washington University-developed database that will serve as a NATIONAL RESOURCE for the analysis of
similar dose escalation programs.
A second national protocol for 3-D treatment planning of lung cancer is currently under development by the Radiation Therapy Oncology Group. Approval is
scheduled for the fall of 1995; Bahman Emami, MD, clinical director of MIR's 3-D program; Mary Graham, MD; and Purdy will chair the MIR/Barnes Hospital studies. liLUJ
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REFLECTIONS
A technology-driven I the mid-1980s, GILBERT JOST, MD, chief of Diagnostic Radiology, and
\MES BLAINE, DSc, director of the Electronic Radiology Laboratory (ERL),
collaboration among
industry and medical
giants promises to make
health care more convenient, more efficient,
and more cost-effective.
With that promise comes
the realization of MIR's
ten-year-old dream of a
high-speed, fiber optic
communications system
to transmit voice, data,
video, and high-resolution images.

orked on the "Fast Packet Project" with Jonathan Turner, PhD, and Jerome Cox,
ScD, of the University's Department of Computer Science. With support from Southwestern Bell and several other corporate sponsors, the researchers' goal was to
develop a high-speed ATM communications system to support the electronic storage,
transmission, and display of medical images. That collaboration, in part, laid the
groundwork for "PROJECT SPECTRUM," a three-year program that will provide uniform integration of patient information from all BJC hospitals, electronic availability of patient records for BJC-affiliated physicians, and accessibility of data and
images from all BJC hospitals.
BJC Health System, Washington University School of Medicine and Mallinckrodt Institute, IBM, Eastman Kodak, and Southwestern Bell comprise Project Spectrum's initial partnership; additional industrial members of the consortium are
anticipated. The project's first phase began in mid-1994 with the development of prototype systems for both clinical information management and electronic image management. High-speed telecommunications links (155 megabits per second) are in place
at all hospitals currently served by Mallinckrodt Institute. A comprehensive clinical
data repository soon will include patient information gleaned from thousands of medical records stored at 15 BJC hospitals and affiliates.
A three-member executive committee steers Project Spectrum — Jost; David
Weiss, director of BJC's management information systems; and Dr. Mark Frisse, associate dean for the School of Medicine's academic information management. In his
capacity on the executive committee, Jost is responsible for coordinating the overall
activities of the project and is specifically responsible for issues related to medical
images.
Blaine and Dr. Michael Kahn, director of medical informatics, are key members
of the project. As project director for clinical information systems, Kahn is responsible for integrating patient information from all of the BJC hospitals. As the University's project director for imaging and communications initiatives, Blaine oversees the
development of efficient, cost-effective ways to transmit diagnostic radiology images
as well as images from other medical specialties across Spectrum's wide-reaching
electronic network.
As the FIRST INTEGRATED HEALTH INFORMATION SYSTEM
nationwide to link an academic medical center with suburban and rural health facilities, Project Spectrum is capable of supporting both video and high-resolution image
transmission to more than 5,000 affiliated physicians in a 250-mile radius. The system
is scheduled for enterprise-wide operation in late 1997. EH
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REFLECTIONS
To many of us "mitosis" may sound like
a foreign language.

To

MICHAEL MACKEY,
a PhD cancer biologist,
this term is a familiar
steppingstone in his
search for an effective
method of treating cancer
with an age-old therapy,
hyperthermia.

The process that cells undergo to achieve normal cell division is called mitosis: After
a cell divides, its DNA must be doubled before the cell can divide again. Premature or
abnormal mitotic events lead to cell death. HYPERTHERMIA uses high temperatures to trick cells into dividing or attempting to divide before the completion of normal mitosis. Based on results from numerous rodent studies and on the assumption
that temperature levels causing rodent cell death elicited the same result in human
cells, researchers and clinicians nationwide followed the principle that hyperthermia
was not effective with temperatures lower than 43° Celsius. But those same high temperatures that kill cancer cells often are not tolerated well by patients and cause technical difficulties with the heat delivery systems.
In studies supported in 1993 by a National Institutes of Health grant, Mackey
discovered that unlike rodent cells, human cell death continues at temperatures as low
as 41.5°C. Further research, aided by computer and mathematical modeling, yielded
important information that challenges accepted hypotheses about the biochemical
basis for premature cell division. For example, conventional theory holds that premature cell division is caused by events occurring during the regulated MITOTIC
PROCESS. Mackey proposes there are "cascades of molecular events" and if any
one of the components of the cascades are present in abnormally high amounts, the
cells can be tricked into dividing before DNA replication is completed. He and Dr.
Paul Swanson, a Washington University surgical pathologist, are examining cells by
electron microscopy to identify new modes of cell killing.
Mackey's original research has numerous spinoffs that all impact on the ultimate goal of clinical hyperthermia: Control the cell growth and stop the tumor from
growing. One aspect (which Mackey calls "Ontogeny Recapitulates Phylogeny")
focuses on a biological notion that embryonic cells from different organisms are very
similar during early development, with each species taking a shared path on its way to
adulthood and developing a series of steady states. Another spinoff involves the identification of distinguishable differences between live organisms and dead organisms by
comparing the rates of specific biochemical processes. One theory states that cells
maintain a homeostatic or steady state even though they are constantly bombarded by
external and internal influences, but another, the dynamic systems theory (also called
chaos), purports that some aspects of biological systems are random or chaotic.
Using a computer model, Mackey unified the two concepts and discovered the rates,
although chaotic, actually mirrored each other, resulting in an overall steady state .
Controlling cell growth is a complex problem at the molecular level, but developing models as Mackey has allows cancer biologists to fine-tune experimentation and
to develop hypotheses that can be tested. Lowering the temperature rate used for
hyperthermia is showing good results in the treatment of deep-seated tumors and
holds promise for a number of site-specific tumors such as lung, prostate, and brain. EH3
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Since the first ML
diagnostic radiology
residents arrived in
1931, more than 800
of the world's brightest
young physicians have
received their radiology,
nuclear medicine, and
radiation

oncology

training at the Institute.
The affiliation between
Washington University
School of Medicine and
the BJC hospital network
provides for a wellspring
of cases from which the

RESIDENTS AND
FELLOWS, as well as
medical students and
technologists, can learn
more about the detection
and healing of diseases.

bur-year diagnostic residency program offers instruction and guidance by recogzed experts in the disciplines of abdominal radiology and ultrasonography, neuroraology, nuclear medicine, vascular and interventional radiology, magnetic resonance
imaging, chest radiology, computed tomography, musculoskeletal and emergency radiology, breast imaging, and pediatric radiology. A specialized five-year program to prepare the clinician scientist for an academic radiology career combines general
diagnostic radiology training, full-time research opportunities, and concentrated
instruction in a radiology subspecialty. As a result of the 1994 merger of the diagnostic
residency programs at Barnes and Jewish hospitals, MIR's 68-member training program is the LARGEST OF ITS KIND in the United States.
MIR's nuclear medicine/nuclear radiology residency program has a strong heritage — five decades of Washington University experience in the application of
radionuclide tracers to the biomedical sciences. Two approved learning experiences
are available: A two-year program, open to physicians with at least one but preferably
two or more years of postgraduate training in another specialty, fulfills the training
requirements for American Board of Nuclear Medicine (ABNM) certification. The oneyear option for applicants who have completed a diagnostic radiology residency meets
the requirements for certification in diagnostic radiology with special competence in
nuclear radiology (and usually allows the trainee also to be certified by the ABNM).
The radiation oncology and medical physics residency programs combine
RESEARCH and CLINICAL EXPERIENCES to strengthen and support the
fight against cancer. Accredited in 1971, the radiation oncology program is available to
applicants who have completed an internship and provides a four-year exposure to a
multidisciplinary approach to the treatment of cancer. During a six-month research
rotation, residents participate in a biology or physics project that is supervised by a
staff member. In the two-year medical physics program, trainees gain experience in
solving fundamental problems in dosimetry, hyperthermia, and three-dimensional

pathways for adminis-

treatment planning.
Graduates of MIR's training programs practice in 48 states and in 25 foreign
countries. As further testimony to Mallinckrodt Institute's reputation as a leader in
education, more than 50 current chairs of academic radiology departments worldwide

tering quality patient

received their training or taught at the Institute. IUU

The Institute's teaching
programs are important

care.
At left, Daniel Keleti, MD, 1994-1995
chief resident, Radiation Oncology
Center.
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REFLECTIONS
rTlhe past academic year was one of accomplishments, strategic planning, and major
JL investments in the academic and clinical futures of Mallinckrodt Institute of Radiology at Washington University. We live in and must respond to several environments
that are all changing rapidly: Washington University, the specialty of radiology, and
the United States health care system. At Mallinckrodt Institute, we have made major
commitments to the traditional academic medical responsibilities of PATIENT
CARE, EDUCATION, AND RESEARCH.
Nationwide, many health care providers are preparing for the onset of managed
care and managed competition by combining services to form health care networks.
Mallinckrodt Institute is playing an important role in the BJC Health System, Missouri's first health care network, by providing the highest quality diagnostic and therapeutic patient care possible.
MIR's diagnostic and radiation oncology residency programs continue to attract
the top radiology candidates in the nation, as is evidenced by the exceptional results of
the yearly Matching Program. We are dedicated to preserving the integrity and quality
of the Institute's residency and fellowship programs while broadening our research
graduate student program.
The Mallinckrodt Institute of Radiology at Washington University Imaging Center is the first step in MIR's major expansion of imaging sciences research. The
IMAGING CENTER, which opened last November, provides a centralized location for studies focusing on positron emission tomography, magnetic resonance imaging, electronic radiology and computer science, neuroimaging, and
radiopharmaceutical development. The growth in our research programs will emphasize collaborations with other Washington University departments.
The past academic year has been a time of growth for the Institute. We have
expanded not only in size (60,000 square feet of new or remodeled research space) but
in strength (138 faculty, 90 of whom are tenured or on tenure track). Through careful
planning and the effective use of our important resources, the Institute can become the
highest rated academic radiology department in the United States. At MIR we are not
just responding to an uncertain world, we are creating changes that will improve our
scholarly activities and consequently provide BETTER SERVICE TO OUR
PATIENTS.

jL, Sfa-W-A
Ronald G. Evens, MD
Director of the Institute
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Steven Winn, MD, (back to camera
recently combined his radiology ski
his previous veterinarian experieni
diagnose an unusual patient — Betsy, a
valuable block rhino in the Saint Louis
Zoo's breeding program for endangered
species. An ultrasound examination
revealed an infection in Betsy's reproductive system.
While the Zoo's modern animal hospital
has conventional X ray capabilities, Zoo
veterinarian Eric Miller (right) calls upon
MIR radiologists to assist in diagnosing
specific problems requiring other imaging
modalities. The long-standing collaboration between the Zoo and Mallinckrodt
Institute plays an important role in maintaining the continuity of certain species for
future generations.

